Obermatt
See Similar Stocks →

Flags

Financial distress

Galectin Therapeutics

NAQ:GALT · US3632252025
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings—
Price/Book74
Dividend Yield1
Revenue Growth—
Profit Growth21
Capital Growth1
TSR 52w84
Leverage1
Liquidity100
Refinancing35
Combined—
Analyst Opinions100
Pro Holdings23
Opinion Changes50
Market Pulse63

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2001
Employees14
Websitegalectintherapeutics.com
ISINUS3632252025
Last UpdateApr 2, 2026
Index & Theme
NephrologyCardiovascularChronic DiseasesHepatologyOncologyBiopharmaBiotechnologyPharmaceutical

Description

Galectin Therapeutics Inc. operates as a clinical stage biopharmaceutical company. The company engages in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The company’s drug candidates a…

Similar Stocks

The companies this stock is ranked against.

Compare Galectin Therapeutics with its peers
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Madrigal Pharmaceuticals
NSQ:MDGL
67
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Actuate Therapeutics
NMQ:ACTU
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Black Diamond Therapeutics
NSQ:BDTX
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →